New research suggests that Arzerra (ofatumumab) may be a good option for people with severe lupus who have reactions to Rituxan (rituximab) infusions.
Published in Clinical Kidney Journal, the study “Ofatumumab treatment in lupus nephritis patients“ reports positive results in four SLE patients treated with Arzerra who developed adverse reactions to Rituxan infusions. Each of these patients suffered from lupus nephritis and initially experienced beneficial effects of Rituxan but developed infusion reactions upon retreatment.
Rituxan and Arzerra are approved by the U.S. Food and Drug Administration for the treatment of certain leukemias and/or lymphomas; Rituxan is also indicated for certain rheumatoid arthritis patients. Neither is an approved treatment for lupus, but Rituxan is allowed to be prescribed off-label for serious diseases like SLE.